Press Releases

ShangPharma Innovation And Icahn School Of Medicine At Mount Sinai Forge Translational Research Collaboration

Medical Health News

ShangPharma Innovation Inc., a global venture capital firm focused on biomedical R&D therapeutics and technologies, and the Icahn School of Medicine at Mount Sinai has entered into a multi-year strategic collaboration to accelerate the development of novel early-stage therapeutics. ShangPharma Innovation will provide funding and pre-clinical research support to further the Icahn School of Medicine at Mount Sinai’s objectives of validating drug targets and establishing programs to discover new therapies.

“This partnership was fueled by the groundbreaking technologies from innovators here at Mount Sinai. Our expertise in commercially-relevant translational research, coupled with ShangPharma Innovation’s drug development capabilities will advance much needed medicines to patients worldwide,” said Erik Lium, PhD, senior vice president of Mount Sinai Innovation Partners at the Icahn School of Medicine at Mount Sinai. 
About Mount Sinai Innovation Partners (MSIP)

MSIP is responsible for driving the real-world application and commercialization of Mount Sinai discoveries and inventions, and the development of research partnerships with industry. Our aim is to translate discoveries and inventions into health care products and services that benefit patients and society. MSIP is accountable for the full spectrum of commercialization activities required to bring Mount Sinai inventions to life. These activities include evaluating, patenting, marketing and licensing new technologies building research, collaborations and partnerships with commercial and nonprofit entities, material transfer and confidentiality, coaching innovators to advance commercially-relevant translational discoveries, and actively fostering an ecosystem of entrepreneurship within the Mount Sinai research and health system communities. For more information, visit www.ip.mountsinai.org.